Publications by authors named "Roei D Mazor"

Erdheim-Chester disease (ECD) is a clonal-inflammatory neoplasm driven by mutations in MAPK pathway proto-oncogenes, such as BRAF. Clinical manifestations are protean, affecting virtually every system. This cohort study analyzed 661 patients with ECD to classify them based on clinical features and mutational profiles using unsupervised clustering.

View Article and Find Full Text PDF

Omidubicel-onlv is an FDA-approved, nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB). A phase 3 study demonstrated improved hematopoietic recovery and decreased infections with omidubicel compared with UCB allogeneic transplantation. We report results of an Expanded Access Program evaluating clinical outcomes in patients with hematologic malignancies following transplantation with omidubicel.

View Article and Find Full Text PDF
Article Synopsis
  • * This study focused on patients with mixed histiocytic neoplasms (MXH) and identified unique genetic mutations, while evaluating how well these patients responded to different treatments—both traditional and targeted therapies.
  • * Results showed that targeted therapies significantly improved treatment outcomes, leading to higher rates of response and lower likelihood of disease progression compared to conventional therapies.
View Article and Find Full Text PDF
Article Synopsis
  • * Recent studies have identified other mutations, like those in PIK3CA, which may also drive LCH independently from MAPK signaling, although their effects were not fully understood until now.
  • * New research using a mouse model shows that PIK3CA mutations can contribute to LCH, and a patient's LCH with this mutation successfully responded to a targeted treatment (alpelisib), highlighting the potential for personalized therapies in treating histiocytic neoplasms.
View Article and Find Full Text PDF

Background: Ovarian cancer (OC) is known for exhibiting low response rates to immune checkpoint inhibitors that activate T cells. However, immunotherapies that activate B cells have not yet been extensively explored and may be a potential target, as B cells that secrete immunoglobulins have been associated with better outcomes in OC. Although the secretion of immunoglobulins is often mediated by the microbiome, it is still unclear what role they play in limiting the progression of OC.

View Article and Find Full Text PDF

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for hematologic malignancies and nonmalignant disorders. Rapid immune reconstitution (IR) following allogeneic HCT has been shown to be associated with improved clinical outcomes and lower infection rates. A global phase 3 trial (ClinicalTrials.

View Article and Find Full Text PDF
Article Synopsis
  • A program was launched to provide free genomic testing for patients with rare cancers worldwide, specifically targeting histiocytosis, germ cell tumors (GCT), and pediatric cancers.
  • Patients were recruited through social media and advocacy groups, and 333 were enrolled, with 288 providing tumor tissue for analysis, resulting in significant clinical benefits for patients receiving genomically guided therapy.
  • The study highlighted the rarity of actionable genomic alterations in ovarian GCTs and demonstrated that direct outreach can effectively build cohorts for studying rare cancers' genomic landscapes.
View Article and Find Full Text PDF

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that frequently infiltrates the peri-kidney space ("hairy kidney" appearance), kidney pelvis and proximal ureters, leading to obstructive uropathy. Here, we analyzed the clinical characteristics, imaging findings and long-term kidney outcome of a large multicenter cohort comprising 195 consecutive patients with ECD. Retroperitoneal peri-kidney or peri-ureteral involvement was detected at diagnosis in 147 patients.

View Article and Find Full Text PDF

The tumor microenvironment hosts antibody-secreting cells (ASCs) associated with a favorable prognosis in several types of cancer. Patient-derived antibodies have diagnostic and therapeutic potential; yet, it remains unclear how antibodies gain autoreactivity and target tumors. Here, we found that somatic hypermutations (SHMs) promote antibody antitumor reactivity against surface autoantigens in high-grade serous ovarian carcinoma (HGSOC).

View Article and Find Full Text PDF

Erdheim-Chester disease (ECD) is characterized by excessive production and accumulation of histiocytes within multiple tissues and organs. ECD patients harbor recurrent mutations of genes associated with the RAS/RAF/MEK/ERK signaling pathway, particularly, the BRAF mutation. Following our previous finding that miR-15a-5p is the most prominently downregulated microRNA in ECD patients compared to healthy individuals, we elucidated its role in ECD pathogenesis.

View Article and Find Full Text PDF

The spillover of animal coronaviruses (aCoVs) to humans has caused SARS, MERS, and COVID-19. While antibody responses displaying cross-reactivity between SARS-CoV-2 and seasonal/common cold human coronaviruses (hCoVs) have been reported, potential cross-reactivity with aCoVs and the diagnostic implications are incompletely understood. Here, we probed for antibody binding against all seven hCoVs and 49 aCoVs represented as 12,924 peptides within a phage-displayed antigen library.

View Article and Find Full Text PDF

The pathogenesis of histiocytic neoplasms is driven by mutations activating the MAPK/ERK pathway, but little is known about the transcriptional and post-transcriptional alterations involved in these neoplasms. We analyzed microRNA (miRNA) expression in plasma samples and tissue biopsies of Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) patients. In silico analysis revealed a potential role of miRNAs in regulating gene expression in these neoplasms as compared with healthy controls (HC).

View Article and Find Full Text PDF
Article Synopsis
  • Erdheim-Chester disease (ECD) is a rare inflammatory cancer that often relies on the MAPK signaling pathway and can be effectively treated with Vemurafenib, especially in patients with a specific BRAF mutation, although some may experience diminished efficacy over time.
  • In a study of three ECD patients who showed insufficient response or disease progression on Vemurafenib alone, treatment was switched to a combination of Vemurafenib and Cobimetinib, resulting in clinical and neurological improvements and regression of lesions in some patients.
  • The findings suggest that combining BRAF and MEK inhibitors could be a viable long-term treatment approach for ECD patients, especially those with central nervous system involvement where standard therapy is
View Article and Find Full Text PDF

Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to nonspecific inflammatory and fibrotic findings on histopathologic review of tissue specimens.

View Article and Find Full Text PDF

Objective: To evaluate the added value of fetal MRI to ultrasound in detecting and specifying callosal anomalies, and its impact on clinical decision making.

Methods: Fetuses with a sonographic diagnosis of an anomalous corpus callosum (CC) who underwent a subsequent fetal brain MRI between 2010 and 2015 were retrospectively evaluated and classified according to the severity of the findings. The findings detected on ultrasound were compared to those detected on MRI.

View Article and Find Full Text PDF

The germinal center (GC) reaction begins with a diverse and expanded group of B cell clones bearing a wide range of antibody affinities. During GC colonization, B cells engage in long-lasting interactions with T follicular helper (Tfh) cells, a process that depends on antigen uptake and antigen presentation to the Tfh cells. How long-lasting T-B interactions and B cell clonal expansion are regulated by antigen presentation remains unclear.

View Article and Find Full Text PDF

Purpose: This study assesses the inter-observer variability of mammographic breast density scoring (BDS) between technologists and radiologists and evaluates the effect of technologist patient referral on the load of adjuvant ultrasounds.

Materials And Methods: In this IRB approved study, a retrospective analysis of 503 prospectively acquired, random mammograms was performed between January and March 2014. Each mammogram was evaluated for BDS independently and blindly by both the performing technologist and the interpreting radiologist.

View Article and Find Full Text PDF

Background: Erdheim-Chester Disease (ECD), a non Langerhans' cell histiocytosis of orphan nature and propensity for multi-systemic presentations, comprises an intricate medical challenge in terms of diagnosis, treatment and complication management.

Objectives: The objectives are to report the clinical, radiological and pathological characteristics, as well as cardinal therapeutic approaches to ECD patients and to provide clinical analyses of the medical chronicles of these complex patients.

Methods: Patients with biopsy proven ECD were audited by a multi-disciplinary team of specialists who formed a coherent timeline of all the substantial clinical events in the evolution of their patients' illness.

View Article and Find Full Text PDF

Erdheim-Chester disease is an orphan condition which involves the ongoing proliferation, migration and infiltration of the typical CD68(+), CD1a(-) histiocytes to various target foci. Consequently, both the infiltrating and fibrosing elements of the disease promote end organ damage and ultimately, failure. Presentation of the Erdheim-Chester disease typically involves longstanding diabetes insipidus in conjunction with intensifying bone pain that classically affects the femurs and tibiae.

View Article and Find Full Text PDF

In 2011 a new syndrome termed 'ASIA Autoimmune/Inflammatory Syndrome Induced by Adjuvants' was defined pointing to summarize for the first time the spectrum of immune-mediated diseases triggered by an adjuvant stimulus such as chronic exposure to silicone, tetramethylpentadecane, pristane, aluminum and other adjuvants, as well as infectious components, that also may have an adjuvant effect. All these environmental factors have been found to induce autoimmunity by themselves both in animal models and in humans: for instance, silicone was associated with siliconosis, aluminum hydroxide with post-vaccination phenomena and macrophagic myofasciitis syndrome. Several mechanisms have been hypothesized to be involved in the onset of adjuvant-induced autoimmunity; a genetic favorable background plays a key role in the appearance on such vaccine-related diseases and also justifies the rarity of these phenomena.

View Article and Find Full Text PDF

Erdheim-Chester Disease (ECD) is a rare form of non Langerhans' cell histiocytosis. Individuals affected by this disease are typically adults between their 5th and 7th decades of life. Males and females are almost equally affected.

View Article and Find Full Text PDF